Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

External Control Arms: Better Than Single-Arm Studies But No Replacement For Randomization

Executive Summary

Synthetic control group derived from historical clinical trial data could augment smaller randomized trials and yield better information than single-arm studies, but this approach should not be viewed as a substitute for randomized trials where feasible, US FDA officials said at a Friends of Cancer Research meeting.

You may also be interested in...



Validation Issues Could Dull Synthetic Data Benefits

Is it real, or is it synthetic? When it comes to drug development data in the future, the answer could be the latter. Datasets that replicate the statistical patterns of real patient populations but carry no risk of privacy disclosures could enable the use of synthetic control arms. However, the biopharma industry and regulators will need assurance that these datasets accurately reflect the population from which they were derived.

Real-World Evidence: US FDA Framework Emphasizes Data Fitness And Study Quality

Agency’s approach to assessing real-world evidence for effectiveness will be guided by three key principles: fitness for use of the underlying data, adequacy of the study design, and satisfactory monitoring and data collection.

Moderna’s Pediatric COVID Vaccine Packaging Spurs Confusion Concerns From CDC Panel

Discrete packaging for authorized dose in 6-11 year-olds is not yet available, so vaccination providers have to use product from a vial labeled for ‘booster doses only’ in adults. ACIP members unanimously endorse use of the mRNA vaccine in individuals ages 6-17 years but urge manufacturers to move away from relying on color to differentiate formulations.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS124362

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel